Get the Stockscreener App
11.54
8.12%
-1.02
Gyre Therapeutics Inc stock is traded at $11.54, with a volume of 63,575.
It is down -8.12% in the last 24 hours and up +5.29% over the past month.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
See More
Previous Close:
$12.56
Open:
$12.52
24h Volume:
63,575
Relative Volume:
0.63
Market Cap:
$990.39M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
123.42
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
-3.67%
1M Performance:
+5.29%
6M Performance:
-3.51%
1Y Performance:
-18.33%
1-Day Range:
$11.54
$12.73
1-Week Range:
$11.54
$12.80
52-Week Range:
$8.26
$26.37
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
11.54 | 990.39M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Gyre Therapeutics president Ma Songjiang sells $49,380 in stock - Investing.com
Gyre Therapeutics Faces Revenue Decline Amidst Future Prospects - TipRanks
Gyre therapeutics president Ma Songjiang sells $46,360 in stock - MSN
Gyre therapeutics president Ma Songjiang sells $45,434 in stock - MSN
Gyre therapeutics president Ma Songjiang sells $46,360 in stock By Investing.com - Investing.com Nigeria
Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares - MarketBeat
Gyre Therapeutics president sells $45,380 in stock - MSN
Gyre therapeutics president Ma Songjiang sells $45,434 in stock By Investing.com - Investing.com Nigeria
Gyre Therapeutics president Ma Songjiang sells shares totaling $50,020 By Investing.com - Investing.com Australia
Gyre Therapeutics president Ma Songjiang sells shares totaling $50,020 - MSN
Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock - MarketBeat
Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock - Armenian Reporter
Gyre therapeutics president Ma Songjiang sells $48,029 in stock - MSN
Gyre therapeutics president Ma Songjiang sells $48,029 in stock By Investing.com - Investing.com Canada
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 14.4% in January - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $22,360.00 in Stock - MarketBeat
Gyre Therapeutics president sells $45,380 in stock By Investing.com - Investing.com Australia
Gyre Therapeutics president Ma Songjiang sells $42,760 in stock - MSN
Gyre Therapeutics president Ma Songjiang sells $42,760 in stock By Investing.com - Investing.com Australia
Gyre Therapeutics president Ma Songjiang sells shares worth $42,960 By Investing.com - Investing.com Nigeria
Gyre Therapeutics president Ma Songjiang sells shares worth $42,960 - MSN
Barclays PLC Has $116,000 Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics president Ma Songjiang sells shares for $42,860 - MSN
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gyre Therapeutics Inc Stock (GYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
Feb 19 '25 |
Sale |
12.29 |
2,000 |
24,580 |
2,865,260 |
| Ma Songjiang | President |
Feb 18 '25 |
Sale |
12.49 |
2,000 |
24,980 |
2,867,260 |
| Ma Songjiang | President |
Feb 14 '25 |
Sale |
11.94 |
2,000 |
23,880 |
2,869,260 |
| Ma Songjiang | President |
Feb 13 '25 |
Sale |
11.69 |
2,000 |
23,380 |
2,871,260 |
| Ma Songjiang | President |
Feb 12 '25 |
Sale |
11.49 |
2,000 |
22,980 |
2,873,260 |
| Ma Songjiang | President |
Feb 10 '25 |
Sale |
11.90 |
2,000 |
23,800 |
2,877,138 |
| Ma Songjiang | President |
Feb 11 '25 |
Sale |
11.52 |
1,878 |
21,635 |
2,875,260 |
| Ma Songjiang | President |
Feb 06 '25 |
Sale |
12.85 |
2,000 |
25,700 |
2,881,138 |
| Ma Songjiang | President |
Feb 07 '25 |
Sale |
12.16 |
2,000 |
24,320 |
2,879,158 |
| Ma Songjiang | President |
Feb 05 '25 |
Sale |
12.39 |
2,000 |
24,789 |
2,883,138 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):